Drug Development and Clinical Trials - TARA-002 is currently being developed for non-muscle invasive bladder cancer (NMIBC), which accounts for approximately 80% of bladder cancer diagnoses in the U.S., with around 65,000 new cases annually[23]. - In the ADVANCED-2 trial, the complete response (CR) rate for BCG-Unresponsive patients at any time was 65.7% (23/35), with a 68.2% CR rate at six months[27]. - For the BCG-Naïve cohort, the CR rate at any time was 72.4% (21/29), with a 66.7% CR rate at six months[28]. - The FDA has provided written feedback supporting a proposed registrational design for a controlled trial in BCG-Naïve patients, agreeing that intravesical chemotherapy is an acceptable comparator to TARA-002[30]. - The ADVANCED-2 trial is expected to enroll 75 to 100 patients with BCG-Unresponsive CIS, designed to be registrational based on FDA guidance[59]. - The company plans to complete enrollment of the STARBORN-1 trial in pediatric patients with lymphatic malformations by the second half of 2026[50]. - TARA-002 has shown a complete response (CR) rate of 100% (5/5) in BCG-Unresponsive patients at six months, with a CR rate of 67% (2/3) at 12 months[60]. - In the BCG-Naïve cohort, the CR rate at any time was 72.4% (21/29), with a CR rate of 66.7% (18/27) at six months and 57.9% (11/19) at 12 months[67]. - The STARBORN-1 trial has been initiated to evaluate the safety and efficacy of TARA-002 in approximately 30 pediatric patients with macrocystic and mixed-cystic lymphatic malformations (LMs)[102]. - The THRIVE-3 trial for IV Choline Chloride is a seamless Phase 2b/3 trial with a primary endpoint of measuring the change in plasma choline concentration over 24 weeks[37]. - In the ongoing Phase 2 STARBORN-1 trial, 80% (8/10) of patients who completed treatment achieved clinical success, with 100% (8/8) success rate at the eight-week assessment[105]. - Among macrocystic patients, 83% (5/6) achieved a complete response (CR), defined as a 90% to 100% reduction in total lymphatic malformation (LM) volume[105]. Safety and Efficacy - The safety profile of TARA-002 in the STARBORN-1 trial has been favorable, with no serious adverse events reported[41]. - The majority of treatment-related adverse events (TRAEs) were Grade 1 and transient, with no Grade 3 or greater TRAEs reported[62]. - The most common adverse events (AEs) reported in the trial were mild to moderate, with no serious AEs noted, and the most frequent AEs included swelling and fatigue[107]. - Two patients in the interim analysis reached the 32-week post-treatment assessment and remain disease-free, indicating potential long-term efficacy of TARA-002[106]. Regulatory Designations and Approvals - TARA-002 has received Breakthrough Therapy Designation from the FDA for the treatment of macrocystic and mixed-cystic lymphatic malformations (LMs) in pediatric patients[38]. - The FDA granted Rare Pediatric Disease Designation (RPDD) for TARA-002 in July 2020, with a potential Priority Review Voucher available upon approval[111]. - In December 2025, the FDA granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) for TARA-002 for treating macrocystic and mixed cystic LMs in pediatric patients[112]. - The FDA has provided written feedback supporting a proposed registrational design for a controlled trial of TARA-002 in BCG-Naïve patients, with the trial expected to initiate in the second half of 2026[69]. - IV Choline Chloride has been granted Orphan Drug Designation (ODD) by the FDA for the prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition (PN)[84]. - The FDA granted Fast Track Designation (FTD) to IV Choline Chloride as a source of choline when oral or enteral nutrition is not possible[85]. Market and Commercialization Strategy - The company aims to build commercial infrastructure to launch and commercialize its products in key geographies, focusing on areas with significant unmet needs[51]. - The company plans to commercialize its products in the U.S. first, followed by other regions, as it builds its commercial organization[145]. - There are currently no approved pharmacotherapies for the treatment of lymphatic malformations (LMs) in the U.S., with existing options being high-risk surgical procedures[148]. - TARA-002 will face competition from existing treatment methods for NMIBC, including intravesical BCG TICE and other approved products[149]. Financial Agreements and Obligations - The company has an exclusive agreement with Chugai Pharmaceutical for the development of TARA-002, which is valid until June 17, 2030[53]. - The company is responsible for all fees and expenses under the Choline Agreement, including milestone payments and tiered royalties based on net sales of IV Choline Chloride[123][126]. - The Choline Agreement remains effective until the last sale of the licensed product, with a payment of $100,000 made to Dr. Buchman after receiving FDA meeting minutes[128]. - A total of $375,000 in milestone payments is agreed upon for achieving regulatory approval milestones, with $100,000 already paid[131]. - The License Agreement with The Feinstein Institute grants an exclusive, worldwide license for developing products related to fatty liver disease, with tiered royalties of 1.0% to 1.5% on net sales[129][130]. Regulatory Compliance and Challenges - The company must navigate extensive regulatory requirements for drug development, including preclinical tests and clinical trials, which can take many years to complete[154]. - The FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate drug efficacy, which is a significant milestone in the product development process[159]. - The FDA's review process for new drug applications (NDA) typically takes ten months for standard applications and six months for priority reviews, highlighting the regulatory timeline for product approval[162]. - The FDA may impose a Risk Evaluation and Mitigation Strategy (REMS) as a condition of NDA approval to ensure the benefits of a product outweigh its risks[164]. - The FDA enforces strict marketing regulations, allowing only claims approved in the product's labeling, with penalties for off-label promotion[175]. - The FDA may require post-approval studies to monitor the safety and efficacy of a product after it reaches the market[164]. Pricing and Reimbursement Landscape - Coverage and reimbursement for pharmaceutical products depend on third-party payors, including government programs like Medicare and Medicaid, which are critical for new product acceptance[203]. - Obtaining coverage and reimbursement approval is a time-consuming process that requires substantial supporting data, with no guarantee of success[206]. - Significant uncertainty exists regarding the future coverage and reimbursement policies for pharmaceutical products, impacting commercialization efforts[204]. - The Inflation Reduction Act (IRA) will eliminate the coverage gap under Medicare Part D starting in 2025, significantly lowering out-of-pocket costs for enrollees[211]. - The IRA requires manufacturers to subsidize 10% of Part D enrollees' prescription costs for brand drugs below the out-of-pocket limit, increasing to 20% once the limit is reached[211]. - Legislative changes under the American Rescue Plan Act of 2021 have eliminated the cap on Medicaid Drug Rebate Program rebates, potentially increasing costs for pharmaceutical manufacturers[210]. Intellectual Property and Exclusivity - TARA-002 is expected to have 12 years of biologic exclusivity if approved by the FDA, with a patent expiring in 2044[136][147]. - IV Choline Chloride has an exclusive license until 2035, with additional patents expiring in 2041[137]. - The company has received two patents related to choline compositions, with expiration dates in 2041, indicating a long-term strategy in this area[150]. - Patent term extensions of up to five years can be applied for after NDA approval, based on the drug's testing and review phases[183]. Environmental and Compliance Regulations - Environmental regulations impact pharmaceutical operations, with potential liabilities for contamination and hazardous substance exposure[218]. - Data privacy and security regulations are evolving, posing compliance challenges and potential penalties for pharmaceutical companies[215]. - The Foreign Corrupt Practices Act mandates compliance with accounting provisions for U.S. listed companies, affecting international operations[214].

Clinical Trials and Product Development - TARA-002 demonstrated a 68% complete response rate at six months in BCG-Unresponsive patients in the ADVANCED-2 trial[1] - The company expects to complete enrollment of the BCG-Unresponsive cohort in the ADVANCED-2 trial in the second half of 2026[1] - The company expects to report interim results from the THRIVE-3 registrational trial of IV Choline Chloride in the second half of 2026[1][4] - TARA-002 received Breakthrough Therapy and Fast Track designations for lymphatic malformations, with a regulatory update expected in the first half of 2026[1][7] - The BCG-Naïve cohort of patients in the ADVANCED-2 trial demonstrated a complete response rate of 72.4% at any time[3] - The majority of treatment-related adverse events for TARA-002 were Grade 1 and transient, with no Grade 3 or greater events reported[3] Financial Performance - Protara incurred a net loss of $17.3 million, or $0.37 per share, for Q4 2025, compared to a net loss of $12.8 million, or $0.48 per share, for the same period in 2024[8] - The net loss for the year ended December 31, 2025, was $57,439,000, compared to a net loss of $44,596,000 in 2024, indicating an increase in losses of approximately 28.8%[20] - Protara reported a net income (loss) per share attributable to common stockholders of $(1.34) for 2025, compared to $(2.17) for 2024, showing an improvement in loss per share[20] Expenses and Assets - Research and development expenses for Q4 2025 increased to $13.1 million from $9.5 million in Q4 2024, and for the full year increased to $42.6 million from $31.7 million in 2024[8] - General and administrative expenses for Q4 2025 rose to $6.0 million from $4.8 million in Q4 2024, and for the full year increased to $21.9 million from $17.5 million in 2024[8] - Total operating expenses for the year ended December 31, 2025, were $64,549,000, up from $49,154,000 in 2024, marking an increase of approximately 31.3%[20] - Research and development expenses rose to $42,633,000 in 2025 from $31,704,000 in 2024, reflecting a growth of about 34.5%[20] Cash and Assets Management - Protara completed an oversubscribed public offering raising $86 million, with cash and investments totaling approximately $198 million as of December 31, 2025, expected to support operations into 2028[1][8] - Protara's total current assets decreased from $172,155,000 in 2024 to $159,504,000 in 2025, a decline of approximately 7.7%[18] - The company's cash and cash equivalents significantly dropped from $162,798,000 in 2024 to $49,657,000 in 2025, representing a decrease of about 69.5%[18] - The company's stockholders' equity increased from $167,134,000 in 2024 to $196,412,000 in 2025, an increase of approximately 17.5%[18] - Protara's total liabilities decreased slightly from $14,320,000 in 2024 to $13,056,000 in 2025, a reduction of about 8.8%[18] Shareholder Information - The weighted-average shares outstanding for basic and diluted earnings per share increased from 20,592,847 in 2024 to 42,836,129 in 2025, more than doubling the share count[20] - The company anticipates ongoing development plans for its product candidates and expects to engage with the U.S. Food and Drug Administration regarding future clinical trials[15]

Core Insights - Protara Therapeutics reported significant clinical and regulatory advancements for its lead candidate TARA-002, particularly in non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) [2][3] - The company is on track to complete enrollment for the BCG-Unresponsive cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 trial for BCG-Naïve patients in the second half of 2026 [1][2] - Financially, Protara completed an oversubscribed public offering raising $86 million, with cash reserves expected to support operations into 2028 [1][9] TARA-002 in NMIBC - TARA-002 demonstrated a complete response (CR) rate of 68% at six months in BCG-Unresponsive patients, with a CR rate of 72.4% in BCG-Naïve patients [1][3] - The Kaplan-Meier estimated probability of maintaining a CR for six months was 71.1% for BCG-Unresponsive patients and 73.1% for BCG-Naïve patients [3][4] - The ADVANCED-2 trial is designed to be registrational based on FDA guidance for BCG-Unresponsive NMIBC [10] TARA-002 in LMs - TARA-002 received Breakthrough Therapy and Fast Track designations from the FDA for the treatment of lymphatic malformations, with a regulatory update expected in the first half of 2026 [1][2][8] - The company is working to expedite the treatment's availability to patients [2] IV Choline Chloride for Patients on Parenteral Support - The THRIVE-3 trial for IV Choline Chloride is ongoing, with interim results anticipated in the second half of 2026 [1][5] - This investigational therapy aims to address choline deficiency in patients dependent on long-term parenteral support [15] Financial Performance - For Q4 2025, Protara reported a net loss of $17.3 million, or $0.37 per share, compared to a net loss of $12.8 million, or $0.48 per share, in Q4 2024 [9][22] - Research and development expenses increased to $13.1 million in Q4 2025 from $9.5 million in the prior year, reflecting the advancement of clinical trials [9][22] - As of December 31, 2025, the company had approximately $198 million in cash and cash equivalents, sufficient to fund operations into 2028 [1][9]

Protara Therapeutics FY Conference Summary Company Overview - **Company**: Protara Therapeutics (NasdaqGM:TARA) - **Lead Program**: TARA-002, a bacterial therapeutic for Non-Muscle Invasive Bladder Cancer (NMIBC) and lymphatic malformations Key Points on TARA-002 and NMIBC - **Mechanism of Action**: TARA-002 is a whole cell bacterial therapeutic engineered to retain antigens while eliminating toxicities associated with traditional treatments. It aims to stimulate a broad immune response without the adverse effects of streptolysin or Streptococcus pyogenes exotoxin [8][10] - **Historical Context**: Originally developed by Chugai Pharmaceutical in the 1970s, TARA-002 (formerly OK-432) has been used in over 65,000 patients in Japan for various cancers, demonstrating significant survival benefits [9][10] - **Current Efficacy Data**: - **BCG-unresponsive Patients**: - 68% complete response (CR) at 6 months, the highest reported in the field [23] - 65% CR at any time [24] - 33% CR at 12 months from a recent update [34] - **BCG-naive Patients**: - 72% CR at any time, 68% CR at 6 months, and 58% CR at 12 months [48] - **Regulatory Pathway**: The FDA has approved a single-arm open-label study for BCG-unresponsive patients, with a focus on CR at 6 months as the primary endpoint [41][57] Competitive Landscape - **Market Positioning**: TARA-002 is positioned as a compelling alternative to existing treatments, with a focus on safety, tolerability, and ease of administration. It is expected to have a significant market share due to its unique mechanism and favorable safety profile [89][92] - **Revenue Potential**: The addressable patient population for TARA-002 is estimated to exceed 20,000 in the frontline plus BCG-exposed settings, which presents a substantial revenue opportunity [41] Lymphatic Malformations Program - **Regulatory Update**: A Type C meeting with the FDA is scheduled, expected to clarify the regulatory path for TARA-002 in treating lymphatic malformations [100] - **Market Opportunity**: The company targets macrocystic and mixed cystic lesions, with an estimated 800 addressable patients annually in the U.S. [110] Choline Program - **Overview**: IV Choline Chloride is aimed at patients on parenteral support, with a significant portion being choline deficient. The FDA has agreed on a pivotal study with a primary endpoint of serum choline elevation [116] Conclusion - Protara Therapeutics is positioned for significant growth with multiple registrational studies underway, focusing on TARA-002 for NMIBC and lymphatic malformations, alongside the choline program. The company emphasizes a strong safety profile, efficacy, and a clear regulatory pathway as key drivers for future success [117][120]

Protara Therapeutics Conference Call Summary Company Overview - **Company**: Protara Therapeutics - **Ticker**: TARA - **Industry**: Biotechnology Key Assets and Development Programs TARA-002 - **Indications**: - Non-muscle invasive bladder cancer (NMIBC) - Lymphatic malformations - **Development Stage**: Late-stage development for both indications [3][4] Mechanism of Action - TARA-002 is a genetically distinct strain of inactivated Streptococcus pyogenes, engineered to retain its immune-stimulating properties [4] - It has been used in Japan for decades as a standard of care for lymphatic malformations and adjunctively with chemotherapy for various cancers [5] Clinical Trials and Data - **ADVANCED-2 Study**: - Focuses on BCG-unresponsive NMIBC patients - Reported a 68% complete response rate at 6 months from 22 patients [9] - Preliminary 12-month complete response rate of 33% from 15 evaluable patients [9] - **ADVANCED-3 Study**: - Aims to utilize TARA-002 in the frontline setting as an alternative to BCG, targeting a significant population due to BCG shortages [6][16] - **STARBORN-1 Study**: - Focused on macrocystic and mixed cystic lymphatic malformations, with ongoing patient enrollment and upcoming FDA engagement for a registrational path [41] Market Opportunity - **Unmet Need**: - Approximately 35% of BCG-eligible patients do not receive BCG due to shortages or intolerance, translating to an annual population of 11,000 to 15,000 patients [25][26] - Potentially addressing tens of thousands of patients annually, including those exposed to BCG [27] - **Competitive Landscape**: - TARA-002 is positioned as a viable alternative in the NMIBC setting, with a focus on ease of use and reliability compared to existing treatments [32] Regulatory Insights - The FDA has indicated that a head-to-head trial against BCG is not necessary, which may facilitate a smoother path to approval [19] Other Programs IV Choline Chloride - **Target Population**: Approximately 35,000 patients in the U.S. on long-term chronic TPN [56] - **Clinical Need**: High prevalence of choline deficiency and liver dysfunction in patients on parenteral nutrition [56] - **Intellectual Property**: Orange Book listed product claim patent extending to 2041, providing exclusivity [62] Financial Considerations - The company is optimistic about pricing strategies based on established benchmarks in the NMIBC setting, allowing flexibility in both NMIBC and lymphatic malformations markets [46] Conclusion - Protara Therapeutics is actively advancing its clinical programs, particularly TARA-002, which addresses significant unmet needs in oncology. The company is well-positioned to capture market share in both NMIBC and lymphatic malformations, with a favorable regulatory outlook and a strong pipeline of assets.

Core Points - Protara Therapeutics held an ASCO GU Update Call to discuss recent developments and updates in their pipeline [1] Group 1 - The call was led by Justine O'Malley, Senior Vice President of Investor Relations and Corporate Affairs [1]

Core Viewpoint - Spirit Airlines has reached a deal with lenders to exit bankruptcy by late spring or early summer, following its second bankruptcy filing in August 2025 due to significant losses and cash shortages [1][2]. Financial Restructuring - The airline's total debt and lease obligations are projected to decrease from $7.4 billion before the Chapter 11 filing to approximately $2.1 billion upon exiting bankruptcy [6]. - Spirit plans to cut costs and improve liquidity to avoid liquidation, focusing on routes and time periods with the highest demand [4][5]. Operational Changes - The airline intends to tighten its network around peak demand periods, increasing aircraft utilization on busy days while reducing capacity during off-peak times [5]. - Spirit is also looking to expand its premium seating options and enhance its loyalty programs to maintain its low-fare positioning while encouraging repeat business [6]. Future Prospects - The deal may pave the way for potential future acquisitions, as the company could consider "potential future industry transactions" once stabilized [7]. - Spirit has announced plans to sell 20 Airbus jetliners to alleviate financial pressures, with the fleet reduction expected to begin in April 2026 [11].

Protara Therapeutics Update Summary Company Overview - **Company**: Protara Therapeutics (NasdaqGM:TARA) - **Focus**: Clinical-stage company developing therapies for cancer and rare diseases, with a lead asset TARA-002 for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations [6][4] Industry Context - **Industry**: Oncology, specifically treatments for NMIBC - **Current Landscape**: The NMIBC treatment paradigm is evolving, with a focus on safety, efficacy, and ease of administration for patients and urologists [6][4] Key Points from the Call Trial Updates - **Trial**: Phase 2 open-label ADVANCED-2 trial of TARA-002 in NMIBC patients - **Cohorts**: Two cohorts - BCG-unresponsive and BCG-naïve - **Data Cutoff**: Data cutoff for the interim analysis was January 2026, with earlier abstracts from October 2025 [4][5] Efficacy and Safety Data - **BCG-unresponsive Cohort**: - Complete response (CR) rates: 66% at any time, 68% at 6 months, and 33% at 12 months - 71% probability of maintaining CR for 6 months - 100% of evaluable responders maintained CR from month 9 to 12 - 62% of participants converted from non-CR to CR at 6 months with reinduction [9][10] - **BCG-naïve Cohort**: - Complete response rates: 72% at any time, 67% at 6 months, and 58% at 12 months - 73% probability of maintaining CR for 6 months - 100% of evaluable responders maintained CR from month 9 to 12 - 67% of reinduced patients converted to CR at month 6 [11][12] Product Profile - **TARA-002**: - Unique mechanism of action as a genetically distinct strain of Strep pyogenes - Demonstrates robust single-agent activity with a favorable safety profile, mostly mild and self-limited local reactions - Administered through simple office-based intravesical installation, making it easy to integrate into existing workflows [8][7] Competitive Advantages - **Best-in-Class Potential**: TARA-002 is positioned as a next-generation investigational therapy with compelling response rates, durability, and safety, addressing priorities for NMIBC patients and urologists [5][6] - **Operational Efficiency**: Off-the-shelf availability and no special preparation or burdensome post-administration protocols enhance its appeal [7][8] Future Outlook - **Enrollment**: Expect to complete enrollment in the BCG-unresponsive cohort in the second half of 2026 - **Next Steps**: Plans to initiate the ADVANCED-3 registrational trial in BCG-naïve patients later in the year [13][14] Additional Insights - **Patient Characteristics**: Approximately 35% of BCG-unresponsive patients had prior treatment with investigational or approved products, indicating a diverse patient population [45][46] - **Reinduction Dynamics**: The mandatory biopsy at 3 months for the BCG-unresponsive cohort may explain higher reinduction rates compared to the BCG-naïve cohort [94][95] - **Market Considerations**: The competitive landscape includes various treatment options, but TARA-002's safety and ease of administration may drive its adoption in community settings [65][66] Conclusion Protara Therapeutics is making significant strides with TARA-002 in the NMIBC treatment landscape, showcasing promising efficacy and safety data. The company is well-positioned to address unmet needs in the oncology space, with a focus on operational efficiency and patient-centric care.

Protara Therapeutics Update Summary Company Overview - **Company**: Protara Therapeutics (NasdaqGM:TARA) - **Focus**: Development of transformative therapies for cancer and rare diseases, with a lead asset TARA-002 for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations [6][10] Industry Context - **Industry**: Oncology, specifically treatments for NMIBC - **Current Landscape**: The NMIBC treatment paradigm is evolving, with a focus on safety, efficacy, and ease of administration for patients and urologists [6][8] Key Points from the Call Trial Updates - **Trial**: Phase II open label ADVANCED-2 trial of TARA-002 in NMIBC patients - **Cohorts**: BCG-unresponsive and BCG-naïve cohorts - **Data Cutoff**: January 2026 for interim results; October 2025 for earlier abstracts [4][12] Efficacy and Safety Data - **BCG-unresponsive Cohort**: - Complete response (CR) rate at any time: 66% - 6-month CR rate: 68% - 12-month CR rate: 33% - Kaplan-Meier estimate for maintaining CR at 6 months: 71% [12][13] - 62% of participants converted from non-CR to CR at 6 months with reinduction [13] - **BCG-naïve Cohort**: - Complete response rate at any time: 72% - 6-month CR rate: 67% - 12-month CR rate: 58% - Kaplan-Meier estimate for maintaining CR at 6 months: 73% [14] Product Profile - **TARA-002**: - Unique mechanism of action as a genetically distinct strain of Streptococcus pyogenes - Off-the-shelf availability and simple administration through intravesical installation - Clean safety profile with mostly mild, transient adverse events [10][11][15] Competitive Advantages - **Positioning**: TARA-002 is positioned as a best-in-class therapy with compelling response rates, durability, and favorable safety profile, addressing priorities for NMIBC patients and urologists [5][8] - **Ease of Use**: No special preparation or burdensome post-administration protocols, making it easy to integrate into existing practice workflows [8][15] Future Outlook - **Enrollment**: Expect to complete enrollment in the BCG-unresponsive cohort in the second half of 2026 [13] - **Next Data Update**: Anticipated at major urologic conferences, with ongoing updates as data matures [30] Market Considerations - **Adoption Factors**: Safety, ease of administration, and efficacy are critical for driving adoption in community settings, where most NMIBC treatment occurs [63][75] - **First Mover Advantage**: While there may be first mover advantages for existing therapies, the evolving landscape of NMIBC treatments may mitigate this [64][75] Additional Insights - **Patient Characteristics**: Approximately 35% of BCG-unresponsive patients had prior treatment with investigational or approved products, which may impact response rates [43][90] - **Reinduction Rates**: Higher reinduction rates in the BCG-unresponsive cohort due to mandatory biopsies capturing microscopic disease [100][101] This summary encapsulates the key points discussed during the Protara Therapeutics update call, highlighting the company's focus on TARA-002 and its potential impact on the NMIBC treatment landscape.

Core Insights - Protara Therapeutics announced updated interim results from the Phase 2 ADVANCED-2 trial for TARA-002, a cell-based therapy for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) [1][2] Group 1: Trial Results - The interim analysis for the BCG-Unresponsive cohort included 35 evaluable participants, with a complete response (CR) rate of 65.7% [3][5] - In the BCG-Unresponsive cohort, the CR rate was 68.2% at six months and 33.3% at 12 months, with a Kaplan-Meier estimated probability of maintaining a CR for six months at 71.1% [5] - The BCG-Naïve cohort had a CR rate of 72.4%, with 66.7% at six months and 57.9% at 12 months, and a six-month maintenance probability of 73.1% [4][5] Group 2: Safety and Tolerability - The majority of treatment-related adverse events (TRAEs) were Grade 1 and transient, with no Grade 3 or greater TRAEs reported [5][6] - Common TRAEs included dysuria, bladder spasm, fatigue, and micturition urgency, most of which resolved shortly after administration [6] Group 3: Future Plans - Protara expects to complete enrollment of the BCG-Unresponsive cohort in the second half of 2026 and has completed enrollment in the BCG-Naïve cohort with 31 patients [8] - The company plans to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in the second half of 2026 [8] Group 4: Product Information - TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator, with mechanisms that activate immune pathways and induce immunogenic cell death [11][12] - The therapy has received Rare Pediatric Disease, Breakthrough, and Fast Track Designations from the U.S. FDA [11]